ABL Bio Joins BIO-Europe 2026 in Cologne
The South Korean biotech firm will seek partnerships for its Grabody platforms at Europe's largest pharmaceutical and biotechnology event.
Updated on Nov. 5, 2026 in Biotech
ABL Bio announced it will attend BIO-Europe 2026 in Cologne, Germany, from November 9 to 11. The company plans to meet with global pharmaceutical and biotech firms to pursue business collaborations for its Grabody-B and Grabody-T platforms.
Why it matters
BIO-Europe is Europe's largest pharmaceutical and biotechnology event, making it a key venue for dealmaking and partnership discussions. The event offers ABL Bio a direct channel to present its platform technology and clinical data to potential collaborators.
The event runs November 9-11, 2026 in Cologne, Germany, and is described as Europe's largest pharmaceutical and biotechnology event. No attendance figures or deal-volume data are provided, and the outcome of ABL Bio's meetings has not been disclosed.
The players
ABL Bio
ABL Bio is a South Korean biotechnology company developing the Grabody antibody platforms and pipeline candidates including Givastomig and Ragistomig.
The details
ABL Bio plans to introduce the technological characteristics of its Grabody-B and Grabody-T platforms and clinical data from key pipelines at the event. Grabody-B is designed to deliver drugs across the blood-brain barrier, and the company has expanded its application range from antibodies to include siRNA and other molecules.
Timeline
November 5, 2026: ABL Bio announces attendance at BIO-Europe 2026.
November 9-11, 2026: BIO-Europe 2026 takes place in Cologne, Germany.
Roadmap
Biotech firms routinely use BIO-Europe as a venue to pursue licensing and collaboration deals with pharmaceutical partners. ABL Bio's participation reflects this established pattern of partnering-driven growth in the sector.
For patients, the practical effect of this event is indirect and depends on whether any partnerships lead to clinical programs. Givastomig is in a Phase 2 trial for combination therapy in gastric cancer, and any future access would depend on trial outcomes and regulatory approval.
The takeaway
Partnership events like BIO-Europe are where early-stage drug platforms often gain the commercial backing needed to advance into later-stage development. Readers should watch for announced deals as a signal of which platforms attract pharmaceutical interest.
Further reading
Explore more coverage in our Biotech section for context on drug-delivery and pipeline developments.
Source note: This article includes information reported by 조선일보.
